AMLX.US Amylyx Pharmaceuticals Inc

Healthcare Pharmaceuticals USA Stocks
29.90 USD
Close of Nov 13, 2026
10.83 41.14
Market cap
USD 3.84B
P/E
-
P/B
5.09x
ROE
-23.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AMLX.US undervalued?

Graham number

The Graham number of Amylyx Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amylyx Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Amylyx Pharmaceuticals Inc yet.

Amylyx Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-d…

Full company profile